Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Pharma Mar SAU (PHMR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.620 +0.100    +0.38%
11:35:28 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Spain
ISIN:  ES0169501022 
  • Volume: 18,867
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 26.620 - 26.620
Pharma Mar 26.620 +0.100 +0.38%

Pharma Mar SAU Company Profile

 
Get an in-depth profile of Pharma Mar SAU, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

515

Equity Type

ORD

Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.

Contact Information

Address Avenida de los Reyes, 1 Pol. Industrial La Mina – Norte
Colmenar Viejo Madrid, 28770
Spain
Phone 34 91 846 60 00
Fax 34 91 846 60 01

Top Executives

Name Age Since Title
Jose Maria Fernandez Sousa-Faro - 1986 Founder, Executive Chairman, CEO & President
Montserrat Andrade Detrell - - Proprietary Director
Eduardo Serra Rexach 76 2021 Independent Other External Director
M. Carlos Solchaga Catalan 78 - Independent Other External Director
Blanca Hernandez Rodriguez - 2019 Independent Director
Maria Sandra Ortega Mera - 2020 Representative Proprietary Director
Emiliano Calvo Aller - 2022 Independent Director
Mariano Esteban Rodriguez - 2022 Independent Coordinating Director
Fernando Martin-Delgado Santos - - Independent Other External Director
Rosa Maria Sanchez-Yebra Alonso - 2022 Independent Director
Soledad Cuenca Miranda - 2023 Independent Director
Pedro Francisco Fernandez Puentes - - Executive Vice-Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHMR Comments

Write your thoughts about Pharma Mar SAU
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jairo Ortiz
Jairo Ortiz Feb 22, 2024 4:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pharma Up
Pharma Up Nov 29, 2023 4:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Marco polo
Pharma Up
Pharma Up Nov 28, 2023 4:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hola
Pharma Up
Pharma Up Nov 22, 2023 8:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🧨🚀
Pharma Up
Pharma Up Nov 13, 2023 6:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
35.44
Pharma Up
Pharma Up Nov 10, 2023 4:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pharma Up
Pharma Up Nov 06, 2023 6:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pharma Up
Pharma Up Nov 02, 2023 7:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pharma Up
Pharma Up Sep 20, 2023 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pharma Up
Pharma Up Sep 19, 2023 11:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email